Neurocrine Biosciences (NBIX) Convertible Debt: 2017-2021
Historic Convertible Debt for Neurocrine Biosciences (NBIX) over the last 4 years, with Sep 2021 value amounting to $330.7 million.
- Neurocrine Biosciences' Convertible Debt was N/A to $330.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $330.7 million, marking a year-over-year change of. This contributed to the annual value of $317.9 million for FY2020, which is 22.24% down from last year.
- Neurocrine Biosciences' Convertible Debt amounted to $330.7 million in Q3 2021, which was up 1.35% from $326.3 million recorded in Q2 2021.
- Neurocrine Biosciences' Convertible Debt's 5-year high stood at $414.1 million during Q1 2020, with a 5-year trough of $317.9 million in Q4 2020.
- Over the past 3 years, Neurocrine Biosciences' median Convertible Debt value was $393.4 million (recorded in 2019), while the average stood at $368.4 million.
- Its Convertible Debt has fluctuated over the past 5 years, first rose by 5.25% in 2020, then declined by 22.24% in 2021.
- Neurocrine Biosciences' Convertible Debt (Quarterly) stood at $369.6 million in 2017, then increased by 5.11% to $388.5 million in 2018, then climbed by 5.23% to $408.8 million in 2019, then dropped by 22.24% to $317.9 million in 2020, then fell by 22.24% to $330.7 million in 2021.
- Its Convertible Debt stands at $330.7 million for Q3 2021, versus $326.3 million for Q2 2021 and $322.0 million for Q1 2021.